Free tool simplifies cancer research
Every cell contains a vast number of proteins, each of which has a specific function, for example, as a receptor for another molecule or an enzyme that catalyzes chemical reactions. Disorders of such mechanisms can seriously affect a cell and cause diseases such as cancer, in which the sick cell functions fundamentally differently from a healthy cell. It is therefore very common for a drug to have a protein as its target, one that the substance either inhibits or stimulates the production or uptake of. At the same time, there are a great many approved drugs with a tried and tested effect on certain diseases but without a known protein target. For such substances, it is said that the mechanism of action is either wholly or partly unknown.
Scientists are therefore interested in developing a relatively straightforward method to identify which proteins are affected by a particular drug. Some such methods are already available, but all have their shortcomings. Researchers at Karolinska Institutet have now made use of these methods to create a new tool that gives more reliable and precise results.
The researchers developed their method by experimenting on lung cancer cells treated with 56 different kinds of drug. For each of the drugs, they first worked out the dose that kills half of the cells after 48 hours (LC50) and then used this dose for all the drugs. Once half of the cells had died, they examined each cell’s proteome (i.e., proteins and their abundances) to ascertain which proteins the drugs targeted. In further experiments, they tested the drugs on other cells from breast and intestinal tumors, and drew conclusions about the extent to which the drugs are specific or general in their targeting of cancer cells.
The results of these experiments are described in a searchable database that the researchers created, while the method itself is detailed in the article published in Nature Communications. The idea is for other researchers to be able to perform similar experiments with other drugs using the same model, and to thus expand the database with more target proteins for more substances.
Source: Read Full Article
